Zhihua Huang

This inventor holds 9 USPTO granted patents and 3 published patent applications and 4 EPO patents. Top assignees: Generon (Shanghai) Corporation Ltd., Evive Biotechnology (Shanghai) Ltd, Itabmed (Hk) Limited. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhihua Huang. Retrieved from https://idiyas.com/inventor/zhihua-huang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 3)

% Patents Active = 88.9

EPO Patents = 4 (Patent Applications = 13)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 20(Granted Patents)

Company Filing History:

7 out of 10

Generon (Shanghai) Corporation Ltd.

patents

1 out of 5

Evive Biotechnology (Shanghai) Ltd

Years Active: 2013-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577305 - MULTISPECIFIC ANTIGEN BINDING PROTEINS CAPABLE OF BINDING CD19 AND CD3, AND USE THEREOF (2026-03-17),

2. 12460000 - Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof (2025-11-04),

3. 10870701 - Multispecific fab fusion proteins and use thereof (2020-12-22),

4. 9642917 - Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases (2017-05-09),

5. 9629898 - Use of interleukin-22 in treating viral hepatitis (2017-04-25),

6. 9352024 - Uses of interleukin-22(IL-22) in treating and preventing nerve damage diseases or neurodegenerative diseases (2016-05-31),

7. 9273108 - Recombinant human G-CSF dimer and use thereof for the treatment of neurological diseases (2016-03-01),

8. 8945528 - Use of interleukin-22 in treating viral hepatitis (2015-02-03),

9. 8557546 - Recombinant human G-CSF dimer and use thereof for the treatment of neurological diseases (2013-10-15),

Title: Zhihua Huang: Innovator in Cancer Treatment

Introduction

Zhihua Huang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of cancer treatment through his innovative research and development of bispecific antigen binding proteins. With a total of 9 patents to his name, Huang's work is paving the way for new therapeutic approaches in oncology.

Latest Patents

Huang's latest patents include groundbreaking inventions such as "Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof." This invention provides bispecific antigen binding proteins (BSAPs) that specifically bind to CD3 and a tumor antigen, such as CD19. The applications of these BSAPs extend to the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the BSAPs. Another notable patent is "Multispecific fab fusion proteins and use thereof," which introduces multispecific Fab fusion proteins (MSFP) that specifically bind to CD3 and EpCAM. This invention also outlines the uses of MSFPs for pharmaceutical compositions, cancer treatment methods, and related kits.

Career Highlights

Zhihua Huang has worked with notable companies in the biotechnology sector, including Generon (Shanghai) Corporation Ltd. and Itabmed (HK) Limited. His experience in these organizations has contributed to his expertise in developing innovative cancer therapies.

Collaborations

Huang has collaborated with several professionals in his field, including Xiaoqiang Yan and Yuliang Huang, who is a woman. These collaborations have further enhanced his research and development efforts in cancer treatment.

Conclusion

Zhihua Huang's contributions to cancer treatment through his innovative patents and collaborations highlight his role as a leading inventor in the biotechnology field. His work continues to inspire advancements in therapeutic approaches for cancer patients.

Profile summary based on public USPTO records.